Canadian medical cannabis company Canopy Growth has accused GW Pharma of using a patented technological process to produce its flagship epilepsy treatment, Epidiolex, without authorisation.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 July 2022 The dispute centres on a process for extracting CBD from cannabis plant material, which anticipates the use of CBD as an anti-epileptic treatment.
18 May 2021 Patenting cannabinoids is an established practice in life sciences, but there are a host of other controlled substances in the field of psychoactives that companies have been rushing to patent.
7 February 2020 The UK Intellectual Property Office has blocked Canadian brand Vivo Cannabis from registering ‘Lumina’ as a trademark, after an opposition from an Italian pharmaceutical company.